Bajaj Healthcare Ltd
Incorporated in 1993, Bajaj Healthcare Ltd manufactures a wide range of Active Pharmaceutical Ingredients and Formulations[1]
- Market Cap ₹ 1,166 Cr.
- Current Price ₹ 422
- High / Low ₹ 466 / 263
- Stock P/E 34.1
- Book Value ₹ 162
- Dividend Yield 0.24 %
- ROCE 8.23 %
- ROE -12.2 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
Cons
- Stock is trading at 2.61 times its book value
- Promoter holding has decreased over last quarter: -8.54%
- The company has delivered a poor sales growth of 5.04% over past five years.
- Company has a low return on equity of 7.77% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
171 | 205 | 218 | 223 | 231 | 327 | 370 | 410 | 657 | 680 | 646 | 473 | 508 | |
158 | 186 | 189 | 193 | 200 | 288 | 327 | 362 | 521 | 561 | 534 | 397 | 423 | |
Operating Profit | 13 | 19 | 29 | 30 | 31 | 39 | 43 | 48 | 136 | 119 | 112 | 76 | 85 |
OPM % | 7% | 9% | 13% | 14% | 13% | 12% | 12% | 12% | 21% | 17% | 17% | 16% | 17% |
0 | 0 | 0 | 0 | 2 | 2 | 1 | 7 | 7 | 1 | -19 | -105 | -39 | |
Interest | 6 | 7 | 8 | 8 | 8 | 8 | 8 | 7 | 8 | 13 | 18 | 30 | 29 |
Depreciation | 8 | 9 | 9 | 9 | 11 | 11 | 11 | 12 | 16 | 18 | 17 | 28 | 28 |
Profit before tax | -2 | 3 | 12 | 14 | 14 | 23 | 24 | 36 | 119 | 90 | 58 | -86 | -12 |
Tax % | -31% | 40% | 37% | 39% | 43% | 33% | 33% | 30% | 30% | 20% | 25% | -3% | |
-1 | 2 | 8 | 8 | 8 | 15 | 16 | 25 | 83 | 71 | 43 | -84 | -16 | |
EPS in Rs | -1.18 | 2.19 | 8.34 | 3.04 | 2.83 | 5.50 | 5.91 | 9.14 | 30.11 | 25.87 | 15.59 | -30.36 | -5.63 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 5% | 0% | 0% | 5% | 6% | 6% | -3% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 5% |
3 Years: | -10% |
TTM: | -2% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -15% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 32% |
3 Years: | 2% |
1 Year: | 11% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 14% |
3 Years: | 8% |
Last Year: | -12% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 2 | 2 | 2 | 7 | 7 | 7 | 7 | 14 | 14 | 14 | 14 | 14 | 16 |
Reserves | 26 | 28 | 78 | 82 | 92 | 107 | 122 | 164 | 245 | 315 | 354 | 265 | 430 |
72 | 72 | 70 | 81 | 75 | 87 | 81 | 91 | 181 | 257 | 415 | 333 | 206 | |
31 | 43 | 38 | 39 | 45 | 68 | 57 | 74 | 86 | 136 | 115 | 154 | 152 | |
Total Liabilities | 131 | 145 | 189 | 209 | 219 | 268 | 267 | 343 | 526 | 721 | 898 | 765 | 804 |
54 | 56 | 108 | 130 | 128 | 127 | 128 | 162 | 208 | 270 | 366 | 253 | 240 | |
CWIP | 5 | 3 | 1 | 1 | 0 | 2 | 1 | 5 | 57 | 52 | 22 | 7 | 10 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 |
72 | 87 | 79 | 78 | 91 | 140 | 137 | 170 | 260 | 399 | 510 | 506 | 554 | |
Total Assets | 131 | 145 | 189 | 209 | 219 | 268 | 267 | 343 | 526 | 721 | 898 | 765 | 804 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
14 | 17 | 28 | 25 | 22 | 17 | 25 | 21 | 44 | 1 | -22 | 92 | |
-8 | -9 | -17 | -31 | -8 | -12 | -13 | -28 | -109 | -75 | -93 | -11 | |
-7 | -8 | -11 | 5 | -13 | 2 | -13 | 3 | 75 | 62 | 131 | -97 | |
Net Cash Flow | -0 | 1 | -0 | -0 | 0 | 7 | -0 | -4 | 10 | -12 | 16 | -16 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 95 | 98 | 86 | 70 | 83 | 90 | 77 | 88 | 55 | 99 | 110 | 139 |
Inventory Days | 43 | 51 | 50 | 56 | 45 | 57 | 45 | 54 | 94 | 143 | 199 | 206 |
Days Payable | 51 | 68 | 63 | 46 | 51 | 74 | 45 | 80 | 67 | 94 | 81 | 128 |
Cash Conversion Cycle | 87 | 81 | 73 | 80 | 78 | 73 | 77 | 62 | 82 | 148 | 228 | 217 |
Working Capital Days | 71 | 62 | 52 | 52 | 58 | 61 | 66 | 76 | 90 | 142 | 208 | 226 |
ROCE % | 5% | 10% | 16% | 13% | 13% | 16% | 16% | 18% | 36% | 20% | 14% | 8% |
Documents
Announcements
-
Company Entering Into A CDMO Contract With UK/ EU Based
Companies
9 Dec - Bajaj Healthcare enters CDMO contract for 15 new APIs.
-
Approval From Therapeutic Goods Administration (TGA), Australia
6 Dec - Bajaj Healthcare's API site approved by TGA, Australia.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Nov - Newspaper Publication for the financial results for the half year ended 30th September, 2024
-
Investor Release
14 Nov - Bajaj Healthcare reports strong Q2 FY25 financial results.
-
Board Meeting Outcome for Outcome Of Board Meeting
14 Nov - Board approved quarterly standalone financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1][2][3]
BHL is focused on development, supply, manufacturing of Amino Acids, Nutritional Supplements and Active Pharma Ingredients for Pharmaceutical, Nutraceuticals and Food industries. It manufactures active pharmaceutical ingredients and formulations in the form of tablets, capsules, powder, etc. for ~550+ clients, exporting bulk drugs to ~62+ countries in Europe, USA, Africa, Australia, etc.